Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Oct - Newspaper Advertisement - Special Window for Transfer and Dematerialization of Physical Securities.
Source: Bse
Abbott India Limited (ABBOTINDIA)
Large CapPharma stocks · Large cap · NSE
Abbott India Limited operates in the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals17 Oct 2026 · screener
Latest result12 Aug, 07:18 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
58Neutralfull bear SMA stack · SMA20 +1.5% / mo · MACD − · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 31
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
ABBOTINDIAD candles · FIT view+2.9%Latest close ₹25905.00 on 2026-10-19
Bar
-0.5%
RSI
45
MACD hist
-35.45
52W pos
14%
2026-10-19O ₹26040.00H ₹26145.00L ₹25805.00C ₹25905.00Vol 2,009 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
ABBOTINDIANifty PharmaNifty 500
- ABBOTINDIA
- -8.4%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -2.8 pp
Chart stats
19 Oct 2026- From 52W high
- -15.5%
- 52W range position
- 14%
- ATR (14)
- 2.1%
- Volume vs 20D
- 0.26x
- Avg traded value
- ₹15.7 Cr
- 20D price channel
- ₹25,475 - ₹27,850
₹30,655
₹25,135 - ₹30,655
₹546
Latest completed session
20-session average
19.3% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · UNDERVALUED62
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good60
Revenue +4.4% · PAT +17.2% YoY
Technical
Neutral58
Price trend and sector-relative-strength timing.
Valuation
Legacy model+24.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence86
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Good · 60/100Rev +4% YoY · PAT +17% YoY · margin expansion · +6% QoQ · operating leverage
Filed 12 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,814 Cr | +4.4% | +6.1% |
| EBITDA | ₹522 Cr | +17.0% | +8.5% |
| Operating margin | 29.0% | +300 bps | +100 bps |
| PAT | ₹429 Cr | +17.2% | +8.6% |
| PAT margin | 23.6% | +259 bps | +55 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 34.40
- P/B
- 11.65
- EV/EBITDA
- 28.35
- Market Cap
- 55611.00Cr
Profitability
- ROE
- 34.40%
- ROCE
- 44.80%
- ROA
- 24.84%
- Dividend Y
- 2.01%
Growth (CAGR)
- Revenue 5Y
- 10.00%
- EPS 5Y
- 17.00%
- Revenue 3Y
- 9.00%
- EPS 3Y
- 18.00%
Balance Sheet
- Debt/Equity
- 0.04
- Interest Coverage
- 75.68×
- Altman Z
- 9.33
- Book Value
- 2247.00
Cash Flow
- FCF Yield
- 1.70%
- FCF Positive Y
- 11/5
- OCF
- 1319.00 Cr
- EPS TTM
- 759.88
Shareholding
- Promoter Hold
- 74.99%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 19%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 6,929+8.1% vs prev
Net Profit
₹ CrLatest: 1,552+9.8% vs prev
Return on Equity
%Latest: 7,390+24851.0% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 45. Wait for confirmation.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 rising (~1.5% over last month) — short-term momentum positive.
- RSI(14) at 45 — rising, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
49
RS percentile
Stage 1 Base / Transition
1M return
-5.0%
3M return
-8.4%
6M return
+1.9%
1Y return
-13.0%
RS 1D
0
RS 20D
+7
Sector rank
#1
Industry rank
-
Stage evidence
- Price is within 2.4% of the 30-week proxy.
- The 30-week proxy changed -0.2% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
unranked
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 90.09+0.01%
RS vs Nifty 50090
Valuation & peers
U-Score 62 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 62 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Premium Compounder
Fundamental score breakdown
U band · UNDERVALUEDValuation5/30
Growth14/25
Quality20/20
Balance Sheet12/15
Cash Flow5/10
Piotroski
8/9 (+5)
Penalties
1
Raw sum
62
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
62/100 · legacy band UNDERVALUED
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 24.2%.
- Quality contributes 20/20 to the score.
Main drags
- Valuation is weaker at 5/30; verify the latest quarterly trend.
- Cash flow is weaker at 5/10; verify the latest quarterly trend.
- Growth is weaker at 14/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
34.4
PB
11.7
EV/EBITDA
28.4
ROE
34.4%
ROCE
44.8%
FCF Yield
1.7%
Debt/Equity
0.0
MoS
+24.2%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
62
Previous: 62
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+24.2%
Previous: +24.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
62
62
62
62
62
61
61
62
62
62
62
62
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹6,198.2
-317.9% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹34,194.6
+24.2% MoS
PEG
1.98
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
GLAXO
Large
GlaxoSmithKline Pharmaceuticals Limited
Pharmaceuticals
match 96
60
40.9
45.6%
+12%
UNDERVALUED
ANTHEM
Large
Anthem Biosciences Limited
Pharmaceuticals
match 95
51
78.1
22.3%
-75%
FAIR VALUE
IPCALAB
Large
IPCA Laboratories Limited
Pharmaceuticals
match 95
45
35.4
15.7%
-336%
WATCHLIST
AJANTPHARM
Large
Ajanta Pharma Limited
Pharmaceuticals
match 95
58
36.7
27.1%
+19%
FAIR VALUE
EMCURE
Large
Emcure Pharmaceuticals Limited
Pharmaceuticals
match 94
58
33.5
20.1%
+26%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Abbott India Limited operates in the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
86Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 99th percentile of the scored universe and 100th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 21 Oct 2026
management-trust-v1
11 docs text-extracted · 1 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
99th percentile
overall median 67 · Pharma: 100th pctile, median 70 · Large: 96th pctile, median 73
Evidence depth
Financial-only
11 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
82
strong · capital discipline
Results
95
strong · quarterly consistency
Trust positives
- ▸Promoter holding is 75%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 1.7%.
- ▸11 years of positive FCF.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Abbott India Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Aug
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 20 Jul - Newspaper Advertisement for Eighty-second Annual General Meeting, E-voting facility and Dividend.
Source: Bse
Annual report
Reg. 34 (1) Annual Report. 20 Jul
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Change in Management 25 May - Abbott India appoints Swati Pathak as Associate Director-Operations effective June 1, 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Jun - Newspaper Advertisement - Special Window for Transfer and Dematerialization of Physical Securities.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 27 May - Newspaper Advertisement - Reminder to Shareholders - Unclaimed Dividends.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 13 May
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 13 May
Source: Bse
Announcement
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 13 May
Source: Bse
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Bse
Annual report
Communication Providing The Weblink Including Path Of Annual Report. 20 Jul - Abbott India shared the 2025-26 annual report web-link under SEBI Regulation 36.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.